AstraZeneca made strides toward the company’s goal of adding heart failure to the conditions that can be treated by Farxiga, putting the diabetes drug ahead of a rival medicine from Eli Lilly.
Novo Nordisk’s sales forecast for 2019 was raised due to growing demand for obesity products and a new injectable treatment for diabetes, which is now the company’s growth engine as insulin sales decline.
Novo Nordisk presented data from three separate studies that highlighted the efficacy of oral semaglutide, an investigational once-daily glucagon-like peptide-1 (GLP-1) analog in a pill. Additionally, data showed the efficacy of Merck’s Januvia on type 2 diabetes patients age 65 and older in comparison to the SGLT2 inhibitor dapagliflozin.
Danish drugmaker Novo Nordisk beat first-quarter 2019 operating profit forecasts, helped by higher sales of the company’s biggest new drug hope, a treatment for type 2 diabetes.
PhaseBio Pharmaceuticals’ antiplatelet drug PB2452 received Breakthrough Therapy designation from the U.S. FDA.
Novo Nordisk submitted the company’s oral semaglutide drug, a pill that management hopes will transform the diabetes market, for approval in the United States.
Novo Nordisk reported solid growth for the company’s new diabetes drug and will submit a tablet version – a key growth hope – for U.S. approval in first-quarter 2019, lifting the Danish drugmaker’s shares.
Eli Lilly.’s top-selling diabetes drug Trulicity significantly reduced the risk of heart attack, stroke and heart-related death in a broad range of people with type 2 diabetes in a large clinical trial.
Eli Lilly’s new two-in-one diabetes drug was successful in lowering blood sugar and reducing weight, sending the company’s shares to a record high and weighing on those of arch-rival Novo Nordisk.
Eli Lilly signed a licensing deal for Chugai Pharmaceutical’s oral non-peptidic GLP-1 receptor agonist OWL833.